Literature DB >> 15896868

Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant.

Juyoung Park1, Peter M Bungay, Robert J Lutz, James J Augsburger, Ronald W Millard, Abhijit Sinha Roy, Rupak K Banerjee.   

Abstract

A 3-dimensional finite element model was developed to simulate pharmacokinetics in the eye following drug administration by intravitreal injection and implant for the treatment of retinal disease. The contributions of (1) convection to the transport of drug through the vitreous and aqueous humor and (2) diffusion of drug in the vitreous were varied to study the drug elimination from a normal and diseased eye. Drug distribution achieved by intravitreal injection was compared to that for the same dose released at a constant rate over 15 h from an implant. The model was constructed for a rabbit eye and validated with experimental data for intravitreal injection of fluorescein. The implant reduced peak concentration by 43% and increased residence time by 71% for the baseline (6x10(-6) cm2/s drug diffusivity in vitreous and 0.1 microL/min vitreous outflow), when compared with that of intravitreal injection. Therefore, the implant could be beneficial in reducing the peak concentration and sustaining release of the drug for a longer duration. Convection has a relatively small influence in the normal eye for high diffusivity drugs (1x10(-5) cm2/s), but could have a significant effect for low diffusivity drugs (1x10(-7) cm2/s) in pathophysiologically elevated fluid outflow across the retina. By interpolating the results of this benchmark study, one could estimate the distributions for drugs of different molecular weight, and assess the effect of variable vitreous outflows associated with different pathophysiological conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15896868     DOI: 10.1016/j.jconrel.2005.03.010

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  21 in total

1.  Computer modeling of drug delivery to the posterior eye: effect of active transport and loss to choroidal blood flow.

Authors:  Ram K Balachandran; Victor H Barocas
Journal:  Pharm Res       Date:  2008-08-05       Impact factor: 4.200

2.  Extended Pharmacokinetic Model of the Rabbit Eye for Intravitreal and Intracameral Injections of Macromolecules: Quantitative Analysis of Anterior and Posterior Elimination Pathways.

Authors:  Marko Lamminsalo; Ella Taskinen; Timo Karvinen; Astrid Subrizi; Lasse Murtomäki; Arto Urtti; Veli-Pekka Ranta
Journal:  Pharm Res       Date:  2018-05-31       Impact factor: 4.200

3.  Theoretical study on the need for laser iridotomy in an implantable collamer lens with a hole using computational fluid dynamics.

Authors:  T Kawamorita; K Shimizu; N Shoji
Journal:  Eye (Lond)       Date:  2017-01-20       Impact factor: 3.775

4.  Ex vivo investigation of ocular tissue distribution following intravitreal administration of connexin43 mimetic peptide using the microdialysis technique and LC-MS/MS.

Authors:  Rohit Bisht; Abhirup Mandal; Ilva D Rupenthal; Ashim K Mitra
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

5.  In vitro and computational modelling of drug delivery across the outer blood-retinal barrier.

Authors:  Alys E Davies; Rachel L Williams; Gaia Lugano; Serban R Pop; Victoria R Kearns
Journal:  Interface Focus       Date:  2020-02-14       Impact factor: 3.906

Review 6.  In Vivo Stability of Therapeutic Proteins.

Authors:  Joachim Schuster; Atanas Koulov; Hanns-Christian Mahler; Pascal Detampel; Joerg Huwyler; Satish Singh; Roman Mathaes
Journal:  Pharm Res       Date:  2020-01-03       Impact factor: 4.200

7.  Influence of dosage form on the intravitreal pharmacokinetics of diclofenac.

Authors:  Chandrasekar Durairaj; Stephen J Kim; Henry F Edelhauser; Jaymin C Shah; Uday B Kompella
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-06-10       Impact factor: 4.799

8.  Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide).

Authors:  Suk Ho Byeon; Oh W Kwon; Ji Hun Song; Sung Eun Kim; Yong Sik Park
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-08-06       Impact factor: 3.117

9.  Modeling of corneal and retinal pharmacokinetics after periocular drug administration.

Authors:  Aniruddha C Amrite; Henry F Edelhauser; Uday B Kompella
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-01       Impact factor: 4.799

Review 10.  Intradermal insulin delivery: a promising future for diabetes management.

Authors:  Michael Hultström; Niclas Roxhed; Lina Nordquist
Journal:  J Diabetes Sci Technol       Date:  2014-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.